Liquidity impact:
The closing of Tranche 2 injects roughly 9.09 million new shares into the market at NOK 3.30 each, raising about NOK 30 million of cash for IDEX. On a balance‑sheet basis this is a modest but meaningful boost to short‑term liquidity, giving the company additional runway to fund product roll‑outs or bridge any near‑term working‑capital gaps. However, the upside is partially offset by the dilution of existing equity – the share count rises by roughly 12‑15 % (depending on the pre‑placement float), which will thin the order book and increase the number of shares available for trading. In practice, you can expect a short‑term uptick in daily volume as investors unwind or reposition their holdings, especially institutional accounts that were allocated in the private placement.
Price‑action outlook:
The immediate price reaction will hinge on how the market perceives the financing. At NOK 3.30 the placement is below the recent trading range (≈ NOK 3.40‑3.55), so the announcement is likely to exert downward pressure as existing shareholders adjust to the dilution and the new shares become tradable. Technical charts will probably show a break of the short‑term support around NOK 3.38, with the 20‑day EMA (≈ NOK 3.42) acting as the next resistance level. If the stock can hold above the EMA on higher volume, it may stabilize and even bounce back to the prior consolidation zone (NOK 3.45‑3.55). Conversely, a failure to defend the EMA could trigger a 3‑5 % pull‑back to the next support near NOK 3.25‑3.20.
Actionable take‑away:
- Short‑term traders: Look for a sell‑the‑news move into the low‑NOK 3.30s on the next 1‑2 trading days; consider short positions or put spreads with a stop just above the 20‑day EMA (≈ NOK 3.42).
- Swing‑oriented investors: If the price rebounds above the EMA on strong volume, a partial long entry around NOK 3.30‑3.35 with a target of NOK 3.55 (the pre‑placement high) and a stop at NOK 3.20 could capture a quick recovery while limiting downside from the dilution effect.
Overall, Tranche 2 will improve cash liquidity but will likely depress the stock in the near term due to dilution and the sub‑market‑price issue price. Monitoring volume‑weighted price action around the EMA will be key to confirming the direction.